TARS Live signals | Maximize Profits with Getagraph.com

SELL 103532 min ago

@ $29.83

Issued: 13 Feb 2024 @ 11:42

Return: 7.27%

Previous signal: Feb 9 - 09:30

Previous signal: Buy

Return: -3.38 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 10:14):

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions...

Stats
Today's Volume	41 758.00
Average Volume	732 154
Market Cap	1.20B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.93
ATR14	$0.144 (0.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Mottiwala Aziz	Buy	12 938	Common Stock
2024-03-18	Mottiwala Aziz	Sell	4 766	Common Stock
2024-03-15	Mottiwala Aziz	Sell	8 148	Restricted Stock Units
2024-03-15	Mottiwala Aziz	Sell	4 790	Restricted Stock Units
2024-03-15	Wahl Bryan	Buy	12 038	Common Stock

INSIDER POWER
31.10
Last 100 transactions
Buy: 1 038 524 \| Sell: 656 594

Volume Correlation

Long: 0.09 (neutral)

Short: -0.84 (strong negative)

Signal:(62.296) Neutral

Tarsus Pharmaceuticals, Correlation

10 Most Positive Correlations
SLDP	0.904
HOOK	0.897
USEG	0.893
RDHL	0.884
VIRX	0.875
SVFD	0.874
ONDS	0.869
XFOR	0.867
MARPS	0.864
PLXP	0.858

10 Most Negative Correlations
ITMR	-0.864
AVEO	-0.862
EWEB	-0.854
HZNP	-0.851
OPNT	-0.844
MICT	-0.841
DVCR	-0.84
BNIXU	-0.834
OCCIP	-0.833
ACIW	-0.832

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tarsus Pharmaceuticals, Correlation - Currency/Commodity

-0.16
( neutral )

-0.48
( neutral )

0.00
( neutral )

-0.27
( neutral )

-0.58
( weak negative )

0.13
( neutral )

Tarsus Pharmaceuticals, Financials

Annual	2023
Revenue:	$17.45M
Gross Profit:	$15.85M (90.87 %)
EPS:	$-4.62

Q4	2023
Revenue:	$13.08M
Gross Profit:	$11.86M (90.70 %)
EPS:	$-1.310

Q3	2023
Revenue:	$1.87M
Gross Profit:	$1.49M (79.85 %)
EPS:	$-1.280

Q2	2023
Revenue:	$15.28M
Gross Profit:	$14.96M (97.93 %)
EPS:	$-1.170

Financial Reports:

No articles found.

Tarsus Pharmaceuticals,

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.